Patients' characteristics and treatment duration
Characteristic . | No. . |
|---|---|
| Patients enrolled | 43 |
| Sex | |
| Male | 26 |
| Female | 17 |
| Age, y, median (range) | 65 (27-79) |
| ECOG performance status, median (range) | 1 (0-3) |
| FAB type | |
| M0 | 5 |
| M1 | 8 |
| M2 | 9 |
| M4 | 12 |
| M5 | 3 |
| M7 | 2 |
| Not classified | 4 |
| Prior MDS | 6 |
| Prior induction therapy | |
| No | 11 |
| Yes | 32 |
| Cytogenetics | |
| Unfavorable | 18 |
| Intermediate | 14 |
| Favorable | 3 |
| Unknown | 8 |
| Patients never treated | 1 |
| No. of cycles received | |
| 1 | 17 |
| 2 | 5 |
| 3 | 1 |
| 4 | 1 |
| 5 | 1 |
Characteristic . | No. . |
|---|---|
| Patients enrolled | 43 |
| Sex | |
| Male | 26 |
| Female | 17 |
| Age, y, median (range) | 65 (27-79) |
| ECOG performance status, median (range) | 1 (0-3) |
| FAB type | |
| M0 | 5 |
| M1 | 8 |
| M2 | 9 |
| M4 | 12 |
| M5 | 3 |
| M7 | 2 |
| Not classified | 4 |
| Prior MDS | 6 |
| Prior induction therapy | |
| No | 11 |
| Yes | 32 |
| Cytogenetics | |
| Unfavorable | 18 |
| Intermediate | 14 |
| Favorable | 3 |
| Unknown | 8 |
| Patients never treated | 1 |
| No. of cycles received | |
| 1 | 17 |
| 2 | 5 |
| 3 | 1 |
| 4 | 1 |
| 5 | 1 |
FAB indicates French-American-British; and MDS, myelodysplastic syndrome.